The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians

After more than two decades with interferon alfa-2a and 2b (IFN) as the only approved drugs in the adjuvant setting for melanoma, new treatment approaches like immune checkpoint inhibitors and BRAF-MEK inhibitors improve the progression free survival (PFS) and also the overall survival (OS). We comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kähler, Katharina C., Blome, Christine, Forschner, Andrea, Gutzmer, Ralf, Hauschild, Axel, Heinzerling, Lucie, Livingstone, Elisabeth, Loquai, Carmen, Müller-Brenne, Tina, Schadendorf, Dirk, Utikal, Jochen, Wagner, Tobias, Augustin, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995230/
https://www.ncbi.nlm.nih.gov/pubmed/29899854
http://dx.doi.org/10.18632/oncotarget.25439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995230/
https://www.ncbi.nlm.nih.gov/pubmed/29899854
http://dx.doi.org/10.18632/oncotarget.25439

Ejemplares similares